Crescent Biopharma (Nasdaq: CBIO) granted stock options as equity inducement awards to three non-executive employees under its 2025 Employment Inducement Incentive Award Plan. The awards cover 65,100 ordinary shares, have a 10-year term, and an exercise price of $16.99 per share, matching the June 25, 2026 Nasdaq closing price.
According to Crescent, the options were material to each employee’s acceptance of employment. Vesting occurs 25% on the first employment anniversary, then monthly over the remaining three years, subject to continuous service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CBIO
-3.02%
9 alerts
-3.02%Session close to close
+4.0%Peak in 6 hr 15 min
$516.15MMarket Cap
1.3xRel. Volume
In the Jun 29 session, CBIO declined 3.02%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +4.0% during that session.
Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
This announcement adds 65,100 inducement option shares at a $16.99 strike, consistent with Crescent’...
Analysis
This announcement adds 65,100 inducement option shares at a $16.99 strike, consistent with Crescent’s recent hiring-related grants. With insider activity dominated by tax-driven sales and short interest near 12.66%, investors may watch future equity usage and clinical milestones closely.
Key Figures
Inducement option shares:65,100 sharesOption exercise price:$16.99Option term:10 years+5 more
8 metrics
Inducement option shares65,100 sharesOptions granted to three non-executive employees under 2025 Inducement Plan
Option exercise price$16.99Exercise price equal to Nasdaq closing price on June 25, 2026
Option term10 yearsTerm of inducement stock options granted June 25, 2026
Current share price$16.99Pre-news market context price for CBIO
52-week range$8.72 – $27.41CBIO 52-week low and high before this announcement
Registered for resale19,580,843 sharesOrdinary shares registered for resale by selling securityholders in 424B3
Shares outstanding27,571,935 sharesOrdinary shares outstanding as of April 24, 2026
Short interest12.66%Short interest as of May 29, 2026 with days-to-cover of 11.27
Equity inducement stock options granted to multiple non-executive employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news, including repeated inducement grants and investor events, has usually seen modestly positive or mixed price reactions, with only one notable negative move.
"to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc."
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
nasdaq listing rule 5635(c)(4)regulatory
"material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
rule 10b5-1regulatory
"under a pre-arranged Rule 10b5-1 instruction adopted on <date>February 25, 2026</date>, solely to cover taxes"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
prospectusregulatory
"This prospectus supplement updates the March 3, 2026 prospectus to cover resale"
A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.
WALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 65,100 shares of the Company’s ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on June 25, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to $16.99, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on June 25, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
What inducement awards did Crescent Biopharma (CBIO) grant on June 25, 2026?
Crescent Biopharma granted options to purchase 65,100 ordinary shares as equity inducement awards to three non-executive employees. According to Crescent, these options were approved under its 2025 Employment Inducement Incentive Award Plan and were material to each employee’s acceptance of employment with the company.
What is the exercise price and term of the new Crescent Biopharma (CBIO) stock options?
The Crescent Biopharma inducement options have a 10-year term and an exercise price of $16.99 per share. According to Crescent, the exercise price equals the June 25, 2026 Nasdaq closing price for its ordinary shares, aligning the awards with the market value on the grant date.
How do the Crescent Biopharma (CBIO) inducement stock options vest for new employees?
The inducement options vest 25% on the first anniversary of each employee’s start date, then monthly thereafter. According to Crescent, one-forty-eighth of the shares vest monthly after year one, with all vesting contingent on the employee’s continuous service with the company.
Why did Crescent Biopharma (CBIO) issue inducement awards under Nasdaq Listing Rule 5635(c)(4)?
Crescent Biopharma issued these stock options as equity inducement awards to support the hiring of three non-executive employees. According to Crescent, the options were material to each employee’s acceptance of employment and were granted in reliance on Nasdaq Listing Rule 5635(c)(4).
How many employees received Crescent Biopharma (CBIO) inducement stock options and under which plan?
Three non-executive employees received the inducement stock options at Crescent Biopharma. According to Crescent, the awards were granted under the Crescent Biopharma 2025 Employment Inducement Incentive Award Plan, as amended, and are also subject to individual option agreements for each grant.
What conditions apply to exercising the new Crescent Biopharma (CBIO) inducement options?
The inducement options can be exercised as they vest, subject to continuous employment and the plan’s terms. According to Crescent, the options follow the Inducement Plan and individual option agreements, with vesting tied to service up to and after the first anniversary date.
